A reverse-phase high-pressure liquid chromatography method for the quantitation of sulbactam in plasma, urine, and tissue is described. The assay used the formation of an imidazole derivative followed by extraction with acetonitrile and dichloromethane and used UV absorbance for detection. The mobile phase consisted of acetonitrile, tetrabutylammonium hydroxide, and phosphate buffer. The assay was linear from 100 ,Lg/ml (g of tissue) to 1 ,Lg/ml (g). Within-and between-batch recovery was >90%. The coefficient of variation was generally <15%. There were no interfering peaks in the quantitation of sulbactam.
Sulbactam is a penicillanic acid sulfone which is a competitive and noncompetitive P-lactamase inhibitor (4, 5) . It is coadministered with cefoperazone to expand the antimicrobial spectrum to include previously 3-lactam-resistant microorganisms (3) . Sulbactam may be assayed in plasma by high-pressure liquid chromatography (HPLC) by using a simple extraction procedure, but the chromatograms show interference from metabolic products and lack the sensitivity to determine sulbactam in tissue (3) .
In this report, the development of a new HPLC method is described. It involved the formation of an imidazole derivative of sulbactam followed by an acetonitrile-dichloromethane phase extraction procedure which resulted in a highly sensitive assay free of interfering metabolic products in plasma, urine, and tissue. The method was used to determine sulbactam levels in human plasma, urine, and prostate tissue. Cefoperazone was also determined in these specimens.
MATERIALS AND METHODS
Twenty-five patients who were to undergo transurethral resection of the prostate for benign hyperplasia or cancer of the prostate were entered into this prospective, randomized study. The study was approved by the Institutional Review Board at the Veterans Administration Hospital, and all the patients gave informed written consent. The patients received cefoperazone (1 g ) plus sulbactam (0.5 g) or cefoperazone (2 g) plus sulbactam (1 g ) intravenously over 10 to 15 min. Urine was obtained at the beginning of surgery, and blood and prostatic tissue were obtained simultaneously during surgery. All specimens were frozen at -70°C within 30 min after collection. Cefoperazone and sulbactam laboratory assay powders were obtained from Pfizer Inc., Groton, Conn.
To determine the recovery and reproducibility of the HPLC method, pooled human plasma was spiked with known quantities of sulbactam, and the specimens were divided into 1-ml portions and frozen at -70°C. The prostate tissue was blotted, weighed, diluted with 2 volumes of 0. A standard curve for sulbactam in pooled plasma was prepared just before the plasma assay by the addition of sulbactam to 1.0 ml of plasma with a microliter syringe. The concentration of sulbactam in the standards ranged from 0 to 100 ,g/ml. A standard curve for the determination of the concentration of sulbactam in prostate tissue was prepared by the addition of 2 to 25 ,ug of sulbactam per g to the tissue supernatant and also included a blank specimen. The tissue supernatant was prepared by adding the same volume of buffer to the tissue preparation before homogenization for the assay. No internal standard was added to any of the samples. Urine specimens were diluted 1:10 with normal urine, and a standard curve was prepared from concentrations of 0 to 100 ,ug/ml.
The imidazole reagent was prepared by dissolving 8.5 g of imidazole (Mallinckrodt, Inc., St. Louis, Mo.) in water, adding 5 N HCI to bring the solution to pH 6.8, and adjusting the volume to 40 ml with water. The derivatization procedure for plasma, urine, and tissue consisted of adding 0.5 ml of the imidazole reagent to 1.0 ml of each specimen and standard. The specimens were vortexed and stored at 4°C overnight to allow the derivatization process to be completed. The specimens were then extracted by the acetonitrile-dichloromethane procedure (6) . The procedure includes the addition of 2.0 ml of acetonitrile to the derivatized specimen in a test tube (13 by 100 mm) to precipitate the plasma proteins, centrifugation at 3,000 x g for 5 min, and decanting of the supernatant into 3.0 ml of dichloromethane in a screw-cap tube (13 by 100 mm). The specimens were mixed and centrifuged as previously described. A sample (15 p1l) of the upper aqueous layer containing the sulbactam imidazole derivative was injected into the HPLC with an automated sample processor by using a fixed-loop injector. The HPLC instrumentation consisted of a WISP automated sample processor, a 510 B pump, a 481 variable wavelength detector (all from Waters Associates, Inc., Milford, Mass.), and a Beckman ODS-5 stainless steel column (Beckman Instruments, Inc., Fullerton, Calif.). The detector settings included a wavelength of 313 nm and 0.05 absorbance units full-scale for plasma and 0.01 absorbance units for tissue. The HPLC mobile phase consisted of 89% 0.1 M P04 buffer (pH 6.1) and 11% acetonitrile. Tetrabutylammonium hydroxide (40%, 2 ml; Fisher Scientific Co., Pittsburgh, Pa.) was added to 1 liter of buffer. The buffer was degassed and filtered through a membrane filter (type Fl-1, 0.45-,um pore size; Millipore Corp., Bedford, Mass.) before use. The flow rate was 2.2 ml/min. The retention time of the sulbactam imidazole derivative was 6.0 min. Other antibiotics (including vancomycin, cefoperazone, cefotaxime, ceftriaxone, cefoxitin, cefamandole, penicillin, ampicillin, chloramphenicol, gentamicin, tobramycin, and amikacin) were added to the plasma to determine whether they interfered with the extraction procedure. All antibiotic concentrations in prostate tissue were corrected for blood contamination (2) .
Because the method involves a two-step procedure (derivatization and extraction), a comparison was made by preparing samples in distilled water only, derivatizing these specimens, and assaying small portions by HPLC. The remainder of the specimens were then extracted by the phase extraction procedure. Similar concentrations of sulbactam were also added to plasma, urine, and tissue to determine the efficiency of the extraction procedure.
Between-and within-batch recoveries were made, and all Cefoperazone was determined without modification as previously described (1) .
RESULTS
Chromatograms of the extracted sulbactam imidazole derivative in human plasma are shown in Fig. 1 . The chromatograms did not contain peaks from body metabolites in plasma, urine, or prostate tissue. An additional peak present at a constant of about 25% of the sulbactam peak in all standards and study specimens was also a contaminant in the laboratory assay powder when it was dissolved in water or added to plasma. The contaminant concentration or ratio did not change with time or incubation. Serum, tissue, and urine blank specimens which did not contain sulbactam were derivatized. Imidazole was added to these blank specimens, and there were no peaks which interfered with the sulbactam assay or had the same retention time as the contaminating peak. The extraction efficiency of the sulbactam imidazole derivative procedure in tissue was >90%. This was in the range of 0.5 to 50 ,ug/g. When the peak height of the sulbactam imidazole derivative extracted from water was compared with that extracted from plasma, the plasma peaks were equivalent to 91.7% of those of the drug extracted from water. This shows that when this procedure was used in the same extracting matrix, the efficiency of the procedure was high. There was no interference from other drugs or classes of antibiotics, among them the penicillins, the cephalosporins (including cefoperazone), vancomycin, chloramphenicol, and the aminoglycosides.
The between-and within-batch reproducibility data for plasma are shown in Table 1 . The reproducibility data for prostate tissue are shown in Table 2 . The within-batch reproducibility for plasma was 96.0 to 99.1%. The betweenbatch reproducibility for plasma was 93.0 to 102.0%. In prostate tissue, sulbactam imidazole derivative concentrations of 5.0 ,ug/g could be detected, and the within-batch recovery was 98.7 to 103.1%. The between-batch reproducibility was 97.2 to 100.5%. The coefficient of variation for between-and within-batch studies was generally <11.4%. The recovery of sulbactam from urine was >90%, and the reproducibility was also 90% (data not shown).
The two-step procedure was linear from 100 ,ug/ml (g of tissue) to 1.0 p.g/ml (g of tissue). The chromatograms did not contain contaminating peaks from metabolic products, and the procedure was reproducible.
Concentrations in plasma, urine, and prostate tissue after the intravenous infusion of either 2.0 g of cefoperazone and 1.0 g of sulbactam or 1.0 g of cefoperazone and 0.5 g of sulbactam are shown in Table 3 .
DISCUSSION
The method for the quantitation of sulbactam was reproducible and did not have interference from cefoperazone or other antimicrobial agents. The small number of patients and short time course did not permit pharmacokinetic calculations in this study. The mean collection time for plasma and tissue specimens was 43.5 ± 11.2 min from the start of the infusion. Urine was collected after the end of the infusion (15 min). Based on these data, it appears that cefoperazone penetrates prostate tissue as well as it does other tissue (1) . Similarly, sulbactam penetrates prostate tissue equally well in the 0.5-and 1.0-g intravenous doses. The prostate tissue penetration was 17.8% of the sulbactam level in plasma for the 1.0-g dose and 25.0% for the 0.5-g dose.
